Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177039 | 0.80 | — | — | |
| SCHEMBL5804796 | 0.77 | — | — | |
| SCHEMBL236145 | 0.69 | CYP2A13 (0.33) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL170248 | 0.69 | SMN1; SMN2 (0.33) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL948434 | 0.68 | ALDH1A1 (0.32) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL3935930 | 0.67 | ALDH1A1 (0.35) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL1582708 | 0.67 | MAPT (0.33) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL1825813 | 0.65 | ALDH1A1 (0.51) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL946157 | 0.65 | CYP2A13 (0.31) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL1744327 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541359-B2 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| US-7504426-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | claimed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| JP-2007528404-A | — | — | 2007-10-11 | — | — | JP | claimed |
| EP-1802574-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | APODACA RICHARD | 2007-01-04 | — | — | US | claimed |
| EP-1734961-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-5981537-A | USEFUL IN THE TREATMENT OF INDIVIDUALS WHO ARE HIV POSITIVE | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| WO-1999019304-A9 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | UPJOHN CO (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0728130-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013267-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | THE UPJOHN COMPANY (US) | 1995-05-18 | — | — | WO | claimed |
| EP-0005379-B1 | PHOTOSENSITIVE COMPOSITIONS CONTAINING CARBONYLIC HALIDES AS ACTIVATORS | Dynachem Corporation (US) | 1981-12-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | CYP2A13 1132/4885ALDH1A1 2389/4885HPGD 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.